Marshall Wace LLP Buys 42,130 Shares of Penumbra, Inc. (NYSE:PEN)

Marshall Wace LLP boosted its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 2,312.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,952 shares of the company's stock after purchasing an additional 42,130 shares during the period. Marshall Wace LLP owned about 0.11% of Penumbra worth $10,438,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Barclays PLC grew its stake in Penumbra by 16.5% in the third quarter. Barclays PLC now owns 18,025 shares of the company's stock valued at $3,502,000 after purchasing an additional 2,559 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Penumbra during the 3rd quarter worth about $367,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Penumbra in the third quarter valued at approximately $6,995,000. Tidal Investments LLC raised its position in shares of Penumbra by 2.7% in the third quarter. Tidal Investments LLC now owns 5,008 shares of the company's stock valued at $973,000 after purchasing an additional 130 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Penumbra by 8.2% during the third quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock worth $67,473,000 after acquiring an additional 24,091 shares during the period. 88.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PEN shares. JPMorgan Chase & Co. lifted their price objective on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Wells Fargo & Company boosted their price target on Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a report on Thursday. Stifel Nicolaus set a $318.00 price target on shares of Penumbra and gave the company a "buy" rating in a research note on Thursday. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research report on Wednesday, February 19th. Finally, Piper Sandler reissued an "overweight" rating and set a $330.00 price target (up from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $302.40.

Penumbra Stock Up 0.8 %

NYSE PEN traded up $2.25 on Friday, hitting $300.50. 608,778 shares of the company were exchanged, compared to its average volume of 424,057. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company has a market cap of $11.62 billion, a PE ratio of 883.82, a PEG ratio of 2.83 and a beta of 0.56. The stock has a fifty day moving average of $276.99 and a 200-day moving average of $254.39. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. As a group, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the completion of the transaction, the executive vice president now directly owns 66,539 shares of the company's stock, valued at $19,125,304.77. This represents a 0.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam Elsesser sold 16,560 shares of Penumbra stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $274.35, for a total transaction of $4,543,236.00. Following the completion of the sale, the chief executive officer now directly owns 63,911 shares in the company, valued at $17,533,982.85. This trade represents a 20.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 128,446 shares of company stock valued at $35,959,193 in the last three months. 5.00% of the stock is currently owned by insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.